We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in the Offing for Agilent (A) This Earnings Season?
Read MoreHide Full Article
Agilent Technologies (A - Free Report) is set to report fiscal first-quarter 2021 results on Feb 16. In the last reported quarter, it delivered an earnings surprise of 7.7%.
The stock outperformed earnings estimates thrice and matched once in the last four quarters, with the average surprise being 12.1%.
Trend in Estimate Revision
For the fiscal first quarter, the Zacks Consensus Estimate for earnings has increased 1.1% to 89 cents per share over the past 30 days. This indicates growth of 9.9% from the year-ago reported figure.
The consensus mark for revenues is pegged at $1.43 billion, implying growth of 5.5% from the year-ago reported figure.
Let’s see how things have shaped up for this announcement.
During the fiscal first quarter, Agilent continued to take all the necessary steps to reduce expenses and expand presence in the expanding healthcare market.
Its expanding product portfolio must have been a key growth driver. The company increased investments in fast-growing markets such as biopharma. This is anticipated to have served as a tailwind for Agilent in the quarter.
Markedly, continued strength in China was witnessed in the quarter across all end markets and business groups.
The company’s Diagnostics and Genomics Group (DGG) is expected to have performed well in the to-be-reported quarter, driven by growth in pharma, as well as strength in genomics.
Also, Life Sciences & Applied Markets Group (LSAG) is expected to have performed well driven by improving conditions across geographies, led by growth in Food and Pharma. Strength in Cell Analysis and Mass Spectrometry is also expected to have aided the results.
Markedly, Agilent Cross Lab Group (ACG) is expected to have expanded in the quarter, driven by improving lab operating environment. Also, broad-based growth was seen across major markets and regions served.
Agilent expanded its share in next-gen sequencing, which is expected to have driven the top line in the pathology business. Also, the API business growth must have given a boost to the top line in the quarter.
The company’s focus on aligning investments toward more attractive growth avenues and innovative product launches is expected to have aided its performance.
The consensus mark for revenues from ACG, DGG and LSAG is pegged at $495 million, $260 million and $667 million, indicating 5.3%, 4.4% and 4.5% year-over-year growth, respectively.
What Our Model Says
Our proven model predicts an earnings beat for Agilent this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is the case here as you will see below.
Earnings ESP: The company has an Earnings ESP of +4.64%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Currently, Agilent has a Zacks Rank #3.
Other Stocks That Warrant a Look
Here are a few other stocks worth considering, as our model shows that these too have the right combination of elements to deliver an earnings beat in the upcoming releases.
Workday, Inc. (WDAY - Free Report) has an Earnings ESP of +0.90% and a Zacks Rank #2.
Lattice Semiconductor Corporation (LSCC - Free Report) has an Earnings ESP of +2.94% and holds a Zacks Rank of 3.
Zacks Top 10 Stocks for 2021
In addition to the stocks discussed above, would you like to know about our 10 best buy-and-hold tickers for the entirety of 2021?
Last year's 2020 Zacks Top 10 Stocks portfolio returned gains as high as +386.8%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Image: Bigstock
What's in the Offing for Agilent (A) This Earnings Season?
Agilent Technologies (A - Free Report) is set to report fiscal first-quarter 2021 results on Feb 16. In the last reported quarter, it delivered an earnings surprise of 7.7%.
The stock outperformed earnings estimates thrice and matched once in the last four quarters, with the average surprise being 12.1%.
Trend in Estimate Revision
For the fiscal first quarter, the Zacks Consensus Estimate for earnings has increased 1.1% to 89 cents per share over the past 30 days. This indicates growth of 9.9% from the year-ago reported figure.
The consensus mark for revenues is pegged at $1.43 billion, implying growth of 5.5% from the year-ago reported figure.
Let’s see how things have shaped up for this announcement.
Agilent Technologies, Inc. Price and EPS Surprise
Agilent Technologies, Inc. price-eps-surprise | Agilent Technologies, Inc. Quote
Factors to Note
During the fiscal first quarter, Agilent continued to take all the necessary steps to reduce expenses and expand presence in the expanding healthcare market.
Its expanding product portfolio must have been a key growth driver. The company increased investments in fast-growing markets such as biopharma. This is anticipated to have served as a tailwind for Agilent in the quarter.
Markedly, continued strength in China was witnessed in the quarter across all end markets and business groups.
The company’s Diagnostics and Genomics Group (DGG) is expected to have performed well in the to-be-reported quarter, driven by growth in pharma, as well as strength in genomics.
Also, Life Sciences & Applied Markets Group (LSAG) is expected to have performed well driven by improving conditions across geographies, led by growth in Food and Pharma. Strength in Cell Analysis and Mass Spectrometry is also expected to have aided the results.
Markedly, Agilent Cross Lab Group (ACG) is expected to have expanded in the quarter, driven by improving lab operating environment. Also, broad-based growth was seen across major markets and regions served.
Agilent expanded its share in next-gen sequencing, which is expected to have driven the top line in the pathology business. Also, the API business growth must have given a boost to the top line in the quarter.
The company’s focus on aligning investments toward more attractive growth avenues and innovative product launches is expected to have aided its performance.
The consensus mark for revenues from ACG, DGG and LSAG is pegged at $495 million, $260 million and $667 million, indicating 5.3%, 4.4% and 4.5% year-over-year growth, respectively.
What Our Model Says
Our proven model predicts an earnings beat for Agilent this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is the case here as you will see below.
Earnings ESP: The company has an Earnings ESP of +4.64%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Currently, Agilent has a Zacks Rank #3.
Other Stocks That Warrant a Look
Here are a few other stocks worth considering, as our model shows that these too have the right combination of elements to deliver an earnings beat in the upcoming releases.
Rocket Companies, Inc. (RKT - Free Report) has an Earnings ESP of +3.12% and a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Workday, Inc. (WDAY - Free Report) has an Earnings ESP of +0.90% and a Zacks Rank #2.
Lattice Semiconductor Corporation (LSCC - Free Report) has an Earnings ESP of +2.94% and holds a Zacks Rank of 3.
Zacks Top 10 Stocks for 2021
In addition to the stocks discussed above, would you like to know about our 10 best buy-and-hold tickers for the entirety of 2021?
Last year's 2020 Zacks Top 10 Stocks portfolio returned gains as high as +386.8%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Access Zacks Top 10 Stocks for 2021 today >>